Sign in

    Kalvista Pharmaceuticals Inc (KALV)

    You might also like

    Business Description

    KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company is primarily focused on developing treatments for hereditary angioedema (HAE), a rare genetic condition characterized by episodes of painful swelling. KalVista does not currently sell any products but is advancing its lead candidate, sebetralstat, through regulatory approval processes and conducting preclinical research on additional therapeutic programs.

    1. Sebetralstat - A novel, small molecule plasma kallikrein inhibitor being developed as the first oral, on-demand therapy for hereditary angioedema (HAE). The drug has completed the phase 3 KONFIDENT trial and is under regulatory review following the submission of a New Drug Application (NDA) in June 2024.

    2. Factor XIIa Inhibitor Program - A preclinical program focused on developing oral Factor XIIa inhibitors for next-generation HAE therapeutics. This program also explores potential applications in other diseases with high unmet medical needs.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Benjamin L. PalleikoChief Executive OfficerMarch 7, 2024Benjamin L. Palleiko was appointed as CEO on March 7, 2024. He joined KalVista in 2016 as CFO and has been instrumental in its growth from a UK-based private research entity to a multinational pre-commercial organization.
    Paul K. AudhyaChief Medical OfficerMay 2021Paul K. Audhya, M.D., M.B.A. has served as CMO since May 2021. He previously held senior roles at Arena Pharmaceuticals, Vertex Pharmaceuticals, and others. He earned his B.A. and M.D. from NYU and an M.B.A. from Pepperdine University.
    Christopher M. YeaChief Development OfficerNovember 2015Christopher M. Yea, Ph.D. has been CDO since November 2015. Prior to KalVista, he was COO at Vantia, Ltd. and led the Biology group at Ferring Pharmaceuticals. He holds a B.Sc. and a Ph.D. in Biochemistry from the University of Bristol, UK.
    Brian PiekosChief Financial OfficerSeptember 9, 2024Brian Piekos was appointed as CFO effective September 9, 2024. He has over 25 years of experience in the biopharmaceutical industry, previously serving as CFO at Elicio Therapeutics and others.
    Jeb LedellChief Operating OfficerDecember 16, 2024Jeb Ledell was appointed as COO effective December 16, 2024. He has over 20 years of leadership experience in biotechnology, previously serving as COO at AVEO Pharmaceuticals and others.
    Laurence Reid, Ph.D.Board MemberNovember 23, 2024Laurence Reid, Ph.D., was appointed to the Board on November 23, 2024. He has over three decades of experience in biotech leadership, previously serving as CEO of Decibel Therapeutics and holding roles at Third Rock Ventures and others.